Insiders Are Buying Exelixis. Should You?

Bristol-Myers Squibb (NYSE: BMY  ) may not have much confidence in the future of Exelixis' (Nasdaq: EXEL  ) XL184, but Exelixis' management seems to. Both its chairman and its CFO have purchased Exelixis shares this week.

Shares spiked 7% yesterday after the Securities & Exchange documents were filed. Co-founder and Chairman Papadopoulos Stelios bought shares worth more than $610,000, while CFO Karbe Frank purchased nearly $50,000 worth.

Insider buying is rarely if ever a bad sign. But in this instance, I have a hard time seeing it as a neon sign flashing "BUY," either.

The price of Exelixis' shares in the near term is pegged to the success of its phase 3 trial testing XL184 against a type of thyroid cancer. Exelixis' management has likely seen more data from previous trials, and pored more thoroughly over the public data, than most outsiders have. However, I'm not sure that gives them much of an advantage in predicting the likelihood of success.

The phase 3 trial data is blinded, so people at the company don't know which patients are receiving the drug, and which are getting placebo. Once the results are known to the executives, they would have inside knowledge, and wouldn't be able to buy shares.

If Papadopoulos and Karbe don't have a huge advantage in predicting the trial's success, then why are they buying? For the same reason anyone buys a biotech company: The reward appears to outweigh the risk. Exelixis doesn't need to become the next Pfizer or Merck to produce stellar returns. Just look at where Exelixis is now, and what it could become shortly:

Company

Number of Drugs on the Market

Market Cap (in millions)

Exelixis

0

$350

Dendreon (Nasdaq: DNDN  )

1

$5,191

Abraxis Bioscience (Nasdaq: ABII  )

1

$2,984

Onyx Pharmaceuticals (Nasdaq: ONXX  )

1

$1,558

Celgene (Nasdaq: CELG  )

4

$23,258

Source: Capital IQ, a division of Standard & Poor's.

If you can stand the risk -- Exelixis will plummet if the trial fails -- the rewards could be huge. Just don't buy solely because an insider did.

Rex Moore offers his take on why insider buying might be a good thing.

Pfizer is a Motley Fool Inside Value recommendation. Exelixis is a Rule Breakers pick. The Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (12)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1283584, ~/Articles/ArticleHandler.aspx, 11/26/2014 9:06:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 17,827.75 12.81 0.07%
S&P 500 2,072.83 5.80 0.28%
NASD 4,787.32 29.07 0.61%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
ABII.DL $0.00 Down +0.00 +0.00%
Abraxis BioScience… CAPS Rating: *****
BMY $58.86 Up +0.34 +0.58%
Bristol-Myers Squi… CAPS Rating: ****
CELG $112.61 Up +1.54 +1.39%
Celgene CAPS Rating: *****
DNDNQ $0.14 Down +0.00 -0.71%
Dendreon Corp CAPS Rating: **
EXEL $1.76 Up +0.04 +2.33%
Exelixis CAPS Rating: ****
ONXX.DL $0.00 Down +0.00 +0.00%
Onyx Pharmaceutica… CAPS Rating: **

Advertisement